EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis

Bowen Li, Yan Huang, Qianli Zou iD

ChemBioChem · 02.05.2023 · 24 (9)

DOI: 10.1002/cbic.202300002 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift ChemBioChem, online erschienen am 29.03.2023. Verfasst von Bowen Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Anhui Medical University, Hefei, 230032, P. R. China. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liver. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 159 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation for Distinguished Young Scholars of Anhui Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver fibrosis is a process of excessive accumulation of extracellular matrix caused by liver injury. Liver fibrosis can progress to cirrhosis or even liver cancer without proper intervention. Until now, no effective therapeutic drugs have been clinically approved for treating liver fibrosis. Hence, the development of safe and effective antifibrotic drugs is particularly important. As a representative biomaterial, peptides have been investigated as key components for constructing antifibrotic nanomaterials given their advantages of biological origination, synthetic availability, and good biocompatibility. Peptides serve as multifunctional motifs in antifibrotic nanomaterials, such as liver‐targeting molecules, antifibrotic molecules, and self‐assembling building blocks for the formation of the nanomaterials. In this review, we focus on peptide‐based nanoarchitectonics for treating liver fibrosis, including nanomaterials modified with liver‐targeting peptides, nanomaterials for the efficient delivery of antifibrotic peptides, and self‐assembled peptide nanomaterials for the delivery of antifibrotic drugs. The design rules of these peptide‐based nanomaterials are described. The antifibrotic mechanisms and effects of these peptide‐based nanomaterials in treating liver fibrosis and related diseases are highlighted. The challenges and future perspectives of using peptide‐based nanoarchitectonics for the treatment of liver fibrosis are discussed. These results are expected to accelerate the rational design and clinical translation of antifibrotic nanomaterials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver CirrhosisLiverHumansPeptidesFibrosisExtracellular Matrix

Stichwörter der Autor:innen

HSCsliver fibrosisnanomaterialspeptidestargeted delivery

Substanzen

Peptides

Autor:innen und Institutionen

  • School of Pharmacy, Anhui Medical University, Hefei, 230032, P. R. China.

ORCID-Profile: Qianli Zou

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation for Distinguished Young Scholars of Anhui Province

Zitieren

APA

Li, B., Huang, Y., & Zou, Q. (2023). Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis. ChemBioChem, 24(9). https://doi.org/10.1002/cbic.202300002

Vancouver

Li B, Huang Y, Zou Q. Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis. ChemBioChem. 2023;24(9). doi:10.1002/cbic.202300002

BibTeX
@article{Li2023,
  author = {Li, Bowen and Huang, Yan and Zou, Qianli},
  title = {Peptide‐Based Nanoarchitectonics for the Treatment of Liver Fibrosis},
  journal = {ChemBioChem},
  year = {2023},
  volume = {24},
  number = {9},
  doi = {10.1002/cbic.202300002}
}
Kostenlos starten →